Does Priority Health Cover Forteo (Teriparatide)?

What Is Forteo and Why Does Coverage Matter?

Forteo (teriparatide) is a recombinant fragment of human parathyroid hormone (PTH 1-34) that works by stimulating new bone formation rather than simply slowing bone loss. The FDA approved teriparatide in November 2002 for postmenopausal women and men with osteoporosis at high fracture risk, and later for glucocorticoid-induced osteoporosis [1]. Because it is an anabolic agent, it occupies a different mechanistic class from antiresorptive drugs such as alendronate or zoledronic acid.

The cost matters immediately. The average wholesale price of a single 28-day Forteo pen runs roughly $3,200 to $3,600. At that price point, even patients with commercial insurance can face hundreds of dollars in monthly cost-sharing on a specialty tier. A 2020 analysis published in the Journal of Bone and Mineral Research found that out-of-pocket cost is one of the top three reasons patients abandon anabolic osteoporosis therapy within the first six months [2]. Understanding exactly what Priority Health requires before it will pay is therefore a direct clinical issue, not just a billing formality.

The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines state: "Anabolic therapy should be considered first-line for patients with very high fracture risk," including those with a prior hip or vertebral fracture, a T-score below -3.0, or multiple fractures [3]. That guideline language matters because it forms the medical-necessity foundation most insurers, including Priority Health, reference in their pharmacy coverage criteria.

How Priority Health's Pharmacy Benefit Structures Forteo Coverage

Priority Health is a Michigan-based health plan operating commercial, Medicare Advantage, and Medicaid (Medicaid Health Plan of Michigan) products. Forteo sits on the specialty tier (Tier 4 or Tier 5) across most of its formularies. Specialty-tier placement means the cost-sharing structure is separate from standard retail pharmacy copays and is often calculated as a percentage of the drug's cost rather than a flat copay.

Prior authorization is required on all Priority Health formulary lines that include teriparatide. The plan's pharmacy benefit manager processes specialty drug requests through a clinical review that typically asks for the following documentation:

1. A DXA (dual-energy X-ray absorptiometry) scan result showing a T-score at or below -2.5 at the spine or hip, or clinical evidence of a fragility fracture [4].
2. Documentation that the patient either completed an adequate trial of a bisphosphonate (generally defined as six to twelve months) or has a documented contraindication or intolerance to bisphosphonates.
3. A prescribing physician attestation that the patient is at high or very high fracture risk, often supported by a FRAX score calculation.
4. Confirmation that the patient does not have conditions listed in the FDA black-box warning for teriparatide, including a history of osteosarcoma, Paget's disease, unexplained alkaline phosphatase elevation, or prior skeletal radiation [1].

The FDA's prescribing information for Forteo carries a black-box warning regarding osteosarcoma risk observed in rat studies at supraphysiologic doses, though a 15-year postmarketing surveillance study (the SEER-based analysis by Gilsenan et al., N=3,253 teriparatide users) found no statistically significant increase in osteosarcoma incidence compared with the general population [5]. Insurers still require this contraindication screen as part of the PA process.

The Clinical Evidence Priority Health's Medical Directors Review

Understanding the evidence behind teriparatide helps when preparing a prior authorization or appeal. Priority Health's medical directors review the same published literature physicians use to make prescribing decisions.

The foundational teriparatide fracture trial is the Fracture Prevention Trial (FPT), a randomized, double-blind, placebo-controlled study (N=1,637 postmenopausal women with prior vertebral fracture). Teriparatide 20 mcg/day reduced new vertebral fractures by 65% relative to placebo (RR 0.35 to 95% CI 0.22 to 0.55, P<0.001) and reduced nonvertebral fragility fractures by 53% (RR 0.47 to 95% CI 0.25 to 0.88, P<0.02) at a median of 21 months [6]. That trial is still the primary efficacy anchor for teriparatide coverage decisions.

For glucocorticoid-induced osteoporosis specifically, the Saag et al. trial (N=428, randomized controlled) showed teriparatide increased lumbar spine BMD by 7.2% vs. 3.4% for risedronate at 18 months and reduced new vertebral fractures by approximately 90% relative to risedronate in a subset analysis [7]. Priority Health's coverage criteria for glucocorticoid-induced osteoporosis often reference this distinction.

The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation, BHOF) guidelines recommend teriparatide for patients with very high fracture risk, defining that threshold as a prior hip fracture, a prior vertebral fracture, or a 10-year hip fracture probability at or above 3% on FRAX [8]. Including a FRAX printout and a BHOF guideline citation in the prior authorization packet strengthens the medical-necessity argument substantially.

The HealthRX clinical team has developed a three-tier documentation framework for teriparatide prior authorization submissions to plans that use NCQA-accredited utilization management criteria. Tier 1 is the minimum viable submission: DXA report, fracture history, and prescriber letter. Tier 2 adds the FRAX score, a bisphosphonate intolerance note, and the relevant AACE or BHOF guideline excerpt. Tier 3, reserved for appeals, adds peer-reviewed trial excerpts (FPT or Saag), a letter from an endocrinologist or rheumatologist, and the patient's radiographic fracture imaging. Plans that use Tier 2 or Tier 3 submissions see meaningfully faster approvals in our internal review of member authorization timelines.

Step-by-Step: Getting Prior Authorization Approved

The prior authorization process for Forteo through Priority Health follows a predictable path. Knowing each step reduces the time from prescription to first injection.

Step 1: Confirm plan formulary status. Call Priority Health Member Services at the number on the insurance card or check the online formulary tool. Confirm the specific plan year formulary, since formulary placements can shift January 1 each year.

Step 2: Collect clinical documentation before submission. Gather the DXA report (within the past 24 months is standard), fracture history with imaging if available, FRAX score, and a bisphosphonate trial or intolerance note. The FDA label requires that prescribers consider whether patients are appropriate candidates based on the osteosarcoma warning criteria [1].

Step 3: Submit the PA through the prescribing physician's office. Priority Health accepts electronic prior authorization submissions through CoverMyMeds or through the provider portal. The plan's standard review window is 72 hours for non-urgent requests and 24 hours for urgent clinical situations, per Michigan managed care regulations.

Step 4: If denied, request a peer-to-peer review. The prescribing physician can request a call with the Priority Health medical director. This conversation is the single highest-yield intervention for reversing an initial denial. A 2022 study in Health Affairs found that peer-to-peer review overturned prior authorization denials in 67% to 75% of cases when the requesting clinician was a specialist in the relevant field [9].

Step 5: File a formal appeal if peer-to-peer fails. Michigan law requires Priority Health to provide a first-level internal appeal decision within 30 days for standard cases and 72 hours for expedited cases. If the internal appeal fails, members have the right to an independent external review through the Michigan Department of Insurance and Financial Services (DIFS).

Alternatives Priority Health May Cover More Readily

If the Forteo PA is denied on the first attempt, several alternatives may carry lower prior authorization barriers on Priority Health formularies.

Bisphosphonates (alendronate, risedronate, zoledronic acid) are generic agents on Tier 1 or Tier 2 for most plans, require no prior authorization, and are guideline-recommended first-line therapy for moderate fracture risk [8]. Alendronate 70 mg weekly costs under $20 per month at most pharmacies.

Denosumab (Prolia) is an anti-RANKL monoclonal antibody given as 60 mg subcutaneously every six months. The FREEDOM trial (N=7,808) showed denosumab reduced vertebral fracture risk by 68% over 36 months vs. placebo [10]. Priority Health typically places Prolia on Tier 3 or Tier 4 with prior authorization, but the PA criteria are often less restrictive than for teriparatide because denosumab is generally positioned as a second-line antiresorptive rather than a third-line anabolic.

Abaloparatide (Tymlos) is the other FDA-approved anabolic PTH-related peptide. The ACTIVE trial (N=2,463) showed abaloparatide 80 mcg/day reduced new vertebral fractures by 86% vs. placebo at 18 months [11]. Priority Health's PA criteria for abaloparatide are structurally similar to those for teriparatide. Some plans prefer one agent over the other based on rebate contracts, so it is worth checking both.

Romosozumab (Evenity) is a sclerostin inhibitor approved for postmenopausal women at very high fracture risk. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fractures by 48% vs. alendronate alone over 24 months [12]. Priority Health's PA for Evenity typically requires the same high-risk documentation as teriparatide, with the additional cardiovascular risk screen required by the FDA black-box warning.

Cost Reduction Options When Coverage Is Limited

Even when Priority Health approves Forteo, specialty-tier cost-sharing can still leave patients with significant monthly expenses. These programs directly reduce what patients pay.

Eli Lilly LillyAnswers. The manufacturer's patient assistance program provides Forteo at no cost to patients who meet income eligibility criteria (generally household income at or below 400% of the federal poverty level and no qualifying prescription drug coverage). Application is available through Lilly's 1-800-545-5979 line.

Lilly Cares Foundation. For patients who have insurance but face high cost-sharing, the Lilly Cares Foundation copay assistance card may reduce out-of-pocket cost to as low as $0 to $30 per month for commercially insured patients. Medicare beneficiaries are not eligible for manufacturer copay programs under federal Anti-Kickback Statute rules.

State pharmaceutical assistance programs. Michigan does not operate a broad state pharmaceutical assistance program comparable to some other states, but the Michigan Department of Health and Human Services administers several programs for low-income older adults. The Michigan Medicare/Medicaid Assistance Program (MMAP) can help identify additional resources.

340B pricing. Patients who receive care at a federally qualified health center (FQHC) or other 340B-covered entity may access teriparatide at substantially reduced acquisition cost. The 340B ceiling price for brand drugs can be 20% to 50% below AWP, and those savings are sometimes passed to patients.

Appeals as a cost-reduction strategy. A successful appeal that moves Forteo from non-covered to covered, or from non-preferred to preferred specialty tier, can reduce monthly cost-sharing from hundreds of dollars to a fixed specialty copay. The financial return on a well-documented appeal is therefore substantial.

What Happens After the 24-Month Course Ends

The FDA label for teriparatide limits lifetime use to 24 months [1]. This is not simply a coverage restriction: the osteosarcoma signal from rat studies, combined with diminishing returns on anabolic stimulation after 24 months, drove the regulatory cap. Priority Health and other payers enforce this limit rigorously.

After completing a teriparatide course, guidelines recommend transitioning to an antiresorptive agent to preserve the bone mineral density gains. The BHOF recommends denosumab or a bisphosphonate as the preferred sequential therapy [8]. A 2019 study in the New England Journal of Medicine (the DATA-Switch extension, N=94) showed that patients who transitioned from teriparatide to denosumab continued to gain BMD for an additional 24 months, while those who stopped all therapy lost the gains within 12 months [13]. Priority Health will cover the sequential antiresorptive under standard pharmacy benefit terms once the teriparatide course concludes.

Physicians should document the sequential therapy plan in the original teriparatide PA request. Some Priority Health medical directors view a clear transition plan as evidence of appropriate clinical stewardship, which can support approval of the initial anabolic course.

Medicare Advantage Plans Through Priority Health

Priority Health administers several Medicare Advantage plans in Michigan. Forteo coverage under Medicare Advantage follows the plan's Part D formulary, which by CMS regulation must cover at least two drugs in the parathyroid hormone analogs class. That requirement means Priority Health Medicare Advantage plans must make teriparatide or abaloparatide available, but the plan can require prior authorization and step therapy.

Under CMS rules finalized in the 2024 Medicare Advantage and Part D Final Rule, plans must process standard prior authorization requests within 72 hours (24 hours for expedited requests) [14]. The same rule requires that any prior authorization approval remain valid for the duration of the prescription course for the approved indication, meaning Priority Health cannot require a new PA every 30 days once the anabolic course is approved.

Medicare beneficiaries on Priority Health who reach the catastrophic coverage phase (out-of-pocket threshold of $2 to 000 in 2025 under the Inflation Reduction Act changes) pay no cost-sharing for covered Part D drugs for the remainder of the plan year. For a drug like Forteo with an AWP over $3,000 per month, many patients will reach the catastrophic threshold by the second or third fill.

Documenting Medical Necessity: A Clinical Checklist

The single most common reason Priority Health denies teriparatide prior authorization on the first submission is incomplete documentation. The following checklist covers what experienced osteoporosis specialists include in every submission.

• DXA scan report with T-scores at spine and hip, dated within 24 months
• Fracture history: date, site, mechanism (fall from standing height qualifies as fragility fracture)
• FRAX score with BMD input, calculated at the WHO FRAX tool
• Bisphosphonate trial: drug name, dose, duration (minimum six months), and reason for discontinuation or contraindication (esophageal disease, renal impairment with GFR <35 mL/min, jaw osteonecrosis history)
• Osteosarcoma risk screen: no history of Paget's disease, no prior skeletal radiation, alkaline phosphatase within normal limits
• Prescriber attestation letter: one to two paragraphs citing the AACE or BHOF guideline and explaining why the specific patient meets very-high-risk criteria
• FRAX printout attached as a separate page

A 2023 systematic review in Osteoporosis International found that complete initial PA submissions for anabolic osteoporosis agents reduced time-to-approval by a mean of 8.4 days compared with incomplete submissions requiring supplemental documentation requests [15].